Authors' Disclosures
Cancer
ONCOLOGY, CANCER
A. Ring reports grants from AstraZeneca, Guardant Health, and Bio-Rad during the conduct of the study; personal fees from AstraZeneca, Daiichi Sankyo, Lilly, Novartis, Pfizer, Roche, Gilead, Stemline, Seagen, and MSD outside the submitted work. L.S. Kilburn reports grants from Cancer Research UK during the conduct of the study. L. Moretti reports grants from Cancer Research UK; grants and nonfinancial support from AstraZeneca; and nonfinancial support from Guardant Health and Bio-Rad during the conduct of the study. I.R. Macpherson reports personal fees from Eli Lilly, AstraZeneca, Daiichi Sankyo, Pfizer, MSD, In3Bio, Roche, Stemline Therapeutics, and Owkin; personal fees and nonfinancial support from Gilead and Novartis outside the submitted work. R.D. Baird reports grants and personal fees from AstraZeneca and Roche-Genentech; personal fees from Daiichi Sankyo, Molecular Partners, Novartis, and Shionigi outside the submitted work. R. Roylance reports other support from NIHR during the conduct of the study; other support from BMS and Roche; personal fees from Pfizer, AstraZeneca, Elli-Lilly, and Daiichi Sankyo outside the submitted work. H. Johnson reports grants from Cancer Research UK; grants and nonfinancial support from AstraZeneca; nonfinancial support from Guardant Health and Bio-Rad during the conduct of the study. M.C. Winter reports personal fees from Novartis, Gilead, Roche, Eli Lilly, and Pfizer outside the submitted work. E. Copson reports nonfinancial support from SECA; personal fees and nonfinancial support from Roche and Novartis; grants and personal fees from AstraZeneca, Daiichi Sankyo, and World Cancer Research Fund; and personal fees from Eli-Lilly, Pfizer, and Menarini-Stemline outside the submitted work. T. Hickish reports grants from Cancer Research UK during the conduct of the study; personal fees from iQ HealthTech outside the submitted work. V. Serra reports grants from ISCIII and AECC during the conduct of the study; grants from AstraZeneca outside the submitted work; in addition, V. Serra has a patent for WO2019122411A1 pending. A. Llop-Guevara reports grants from Asociación Española Contra el Cáncer (AECC, INVES20095LLOP) during the conduct of the study; in addition, A. Llop-Guevara has a patent for WO2019122411A1 pending. J.M. Bliss reports grants from Cancer Research UK; grants and nonfinancial support from AstraZeneca, Puma Biotechnology, AstraZeneca, Novartis, Janssen-Cilag, Merck Sharpe & Dohme, Puma Biotechnology, Pfizer, Roche, and Clovis Oncology; and nonfinancial support from Guardant Health and Bio-Rad during the conduct of the study; and grants and nonfinancial support from Eli Lilly outside the submitted work. N.C. Turner reports advisory board honoraria from AstraZeneca, Lilly, Pfizer, Roche/Genentech, Novartis, GlaxoSmithKline, Repare therapeutics, Relay therapeutics, Zentalis, Gilead, Inivata, Guardant, and Exact Sciences, and research funding from AstraZeneca, Pfizer, Roche/Genentech, Merck Sharpe and Dohme, Guardant Health, Invitae, Inivata, Personalis, and Natera. No disclosures were reported by the other authors.